UK markets closed
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • FTSE 250

    19,123.71
    +430.73 (+2.30%)
     
  • AIM

    896.27
    +10.41 (+1.18%)
     
  • GBP/EUR

    1.1618
    -0.0028 (-0.24%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • BTC-GBP

    17,474.83
    -85.38 (-0.49%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.32 (+2.68%)
     
  • CRUDE OIL

    107.06
    +2.79 (+2.68%)
     
  • GOLD FUTURES

    1,828.10
    -1.70 (-0.09%)
     
  • NIKKEI 225

    26,491.97
    +320.72 (+1.23%)
     
  • HANG SENG

    21,719.06
    +445.19 (+2.09%)
     
  • DAX

    13,118.13
    +205.54 (+1.59%)
     
  • CAC 40

    6,073.35
    +190.02 (+3.23%)
     

Middle East Liquid Biopsy Market - Country Analysis: Focus on Product, Technology, Indication, Sample, Workflow, Circulating Biomarker, Usage, and Country Data - Analysis and Forecast, 2022-2032

·9-min read
ReportLinker
ReportLinker

Middle East Liquid Biopsy Market to Reach $175. 2 Million by 2032. Middle East Liquid Biopsy Market: Industry Overview. In 2021, the Middle East liquid biopsy market was valued at $43.

New York, June 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Middle East Liquid Biopsy Market - Country Analysis: Focus on Product, Technology, Indication, Sample, Workflow, Circulating Biomarker, Usage, and Country Data - Analysis and Forecast, 2022-2032" - https://www.reportlinker.com/p06282681/?utm_source=GNW
7 million, and it is expected to reach $175.2 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032. The Middle East liquid biopsy market is expected to witness high growth due to the rising incidence of cancer, the increasing fund infusions for conducting research to discover novel biomarkers, and the growing emphasis on the use of non-invasive methodologies for performing a liquid biopsy. The constant significant investments by healthcare companies to meet industry demand and the increasing adoption of liquid biopsy among major end users are significant factors propelling the growth of the Middle East liquid biopsy market.

Market Lifecycle Stage

A liquid biopsy is an emerging approach for disease treatment and prevention that considers individual variability in genes, environment, and lifestyle for each person.The ultimate goal of liquid biopsy is to provide the right treatment, to the right patient, at the right time.

The liquid biopsy research is being conducted for several disease areas such as oncology, immunology, neurology, and infectious diseases.Liquid biopsy is one of the most modernized trends in the healthcare industry, which has shown tremendous progress in 2019-2021.

The use of non-invasive liquid biopsy for analyzing fetal cell-free DNA (cfDNA) can offer critical information, which could tell the physician and the mother whether to continue a pregnancy or not.In addition, research is also being conducted to assess the clinical potential of extracellular vesicles (EVs) to screen metabolic disorders, including diabetes.

It is worth mentioning here that EVs contain nucleic acids, particularly microRNA (miRNA), which is an excellent source to monitor the progression of metabolic disorders. With the incorporation of molecular technologies, researchers and clinicians could offer insights regarding the onset of metabolic disorders and the early diagnosis of diabetes-related microvascular complications in patients. Significant fund infusions are being provided to companies and academic research institutes to examine the potential of circulating nucleic acids present in the non-invasive samples, which could offer massive opportunities to the Middle East liquid biopsy market in the forthcoming years.

Impact

• The presence of major service providers of liquid biopsy products in the Middle East region has a significant impact on the market. For instance, Illumina, Inc. provides NovaSeq 6000 S2, Reagent Kit, NovaSeq 6000 S4 reagent kit, and NovaSeq Xp 4-lane kit in the Middle East.
• Companies such as F. Hoffmann-La Roche Ltd offer FoundationOne Liquid. It is a U.S. Food and Drug Administration-approved product that assesses guideline-recommended genes from a simple blood draw method. It is the only FDA-approved blood-based test that analyzes more than 300 genes. The presence of such products has a positive impact on market growth.

Impact of COVID-19

The current Middle East liquid biopsy market study comprises products and services utilized to analyze underlying alterations in circulating biomarkers from non-invasive sample types.Since the market is primarily dominated by the clinical utility of products and services, the COVID-19 pandemic had a high impact on the growth and revenue generated from the market.

The current market assessment has considered information provided by key opinion leaders in the market from both supply and demand sides. Although manufacturers have witnessed low-scale losses due to decreased demand, the losses incurred for the first two quarters of FY2020-2021 are anticipated to be compensated by higher demands in the following two quarters in FY2021.

However, the industry is still expected to be impacted significantly during the period 2020-2022.The low influx of cancer patients in hospitals and diagnostic laboratories has massively impacted the sales of Exact Sciences’ Cologuard test.

In 2020, Exact Sciences Corporation was the market leader in the non-invasive liquid biopsy ecosystem, having a 74.31% share in the Middle East liquid biopsy market. Some respondents also stated that they had to delay their product launches due to the ensuing restrictions, which massively impacted market growth. Nevertheless, they are still planning to launch the respective products within theFY2021. As of the current situation, strategies to bolster sales in the last two quarters in order to negate the impact of the COVID-19 pandemic invariably include aggressive marketing and discounted prices offered for existing portfolios. It is expected that, with the restrictions gradually being removed from several regions around the world, coupled with research activities resuming normalcy, the market will face a low impact on the annual revenue generation.

Market Segmentation

Segmentation 1: by Technology
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Other Technologies

The Middle East liquid biopsy market (by technology) was dominated by the next-generation sequencing (NGS) segment in 2021.The highest share of NGS can be attributed to an increase in demand for oncology assessment.

This is due to the increasing prevalence of cancer, and due to this, the major share of liquid biopsy is expected to be held by NGS.

Segmentation 2: by Workflow
• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis

In 2021, the library preparation segment dominated the Middle East liquid biopsy market (by workflow) due to an increasing number of patients suffering from cancer. According to the data published by the World Health Organization, cancer is a leading cause of death, with nearly 10 million deaths reported in 2020.

Segmentation 3: by Usage
• Research Use Only (RUO)
• Clinical

The Middle East liquid biopsy market (by usage) was dominated by the research use only segment in 2021.This growth was attributed to the academic research and industry collaboration in the Middle East region.

Moreover, the technological advancement in RUO products is boosting the growth of the Middle East liquid biopsy market.

Segmentation 4: by Sample
• Blood
• Urine
• Saliva
• Cerebrospinal Fluid

In 2021, the Middle East liquid biopsy market (by sample) was dominated by the blood segment owing to an increasing number of patients suffering from different cancers.

Segmentation 5: by Circulating Biomarker
• Circulating Tumor Cells (CTCs)
• Cell-Free DNA (cfDNA)
• Circulating Cell-Free RNA
• Exosomes and Extracellular Vesicles
• Other Circulating Biomarkers

The Middle East liquid biopsy market (by circulating biomarker) in 2021 was dominated by the cell-free DNA segment due to an increasing number of research studies pertaining to liquid biopsy segment.

Segmentation 6: by Product
• Tests/Services
• Kits and Consumables
• Instruments

The tests/services segment dominated the Middle East liquid biopsy market (by product) in 2021 due to the continued significant investments by healthcare companies to meet industry demand for tests/services, and the growing adoption of liquid biopsy tests among major end users were the key factors propelling the growth of the segment.

Segmentation 7: by Country
• K.S.A.
• Israel
• Egypt
• U.A.E.
• Iran
• Qatar
• Rest-of-the-Middle East

The K.S.A. generated the highest revenue of $13.5 million in 2021, which is attributed to the R&D advancements in the field of single-cell analysis and the presence of dominating players operating in the Middle East liquid biopsy market.

Recent Developments in Middle East Liquid Biopsy Market

• In October 2020, Bio-Rad Laboratories launched the CFX Opus 96 Dx System and CFX Opus 384 Dx System. The product could multiplex about five samples to offer effective in-vitro diagnostics (IVD) assay development and testing. The product has been commercialized in the Middle East region.
• In March 2021, F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, enabling laboratories to extend their oncology research in-house.
• In June 2019, F. Hoffmann-La Roche Ltd partnered with the Health Authority and an international health insurer, AXA, in Dubai. This partnership would develop funding for diagnostic and treatment for breast, colorectal, and cervical cancers.

Demand – Drivers and Limitations

Following are the demand drivers for the Middle East liquid biopsy market:
• Liquid Biopsy Demand Inclined by Rising Prevalence of Cancer
• Rise in Patient Preference for Non-Invasive Cancer Diagnosis
• Potential of Liquid Biopsy

The market is expected to face some limitations too due to the following challenges:
• False Negatives and Positives
• Existing Diagnostic Confidence in Traditional Tissue-Based Diagnosis Practices

How Can This Report Add Value to An Organization?

Product/Innovation Strategy: The product segment helps the reader understand the types of products, i.e., tests/services, kits and consumables, and instruments. These ecosystems are the primary focus of the study as these are the target of market players in terms of revenue generation. Moreover, the study provides the reader with a detailed understanding of the different applications such as lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, other cancers, and non-oncology disorders.

Growth/Marketing Strategy: The Middle East liquid biopsy market has been dominated significantly by companies such as QIAGEN N.V., PerkinElmer, Inc., F. Thermo Fisher Scientific Inc., and Hoffmann-La Roche Ltd., due to their expansive portfolio and strong geographical presence across the world. Many companies such as Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc., Beckman Coulter, Inc. (Danaher Corporation), Illumina, Inc., and Bio-Rad Laboratories, Inc. lie in the low growth and low market share segment. Most key market players in the Middle East liquid biopsy market are categorized under the low growth and low market share segment. The low market share of these companies is primarily due to limited products with respect to the Middle East liquid biopsy market in comparison to other segments of these companies. Also, the lack of synergistic activities with respect to the market is responsible for the low growth of these companies.

Competitive Strategy: Key players in the Middle East liquid biopsy market analyzed and profiled in the study have involved the oncology application-based product manufacturers that provide liquid biopsy tests and services.Moreover, a detailed competitive benchmarking of the players operating in the Middle East liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:
• Bio-Rad Laboratories, Inc.
• Bioscience Institute S.p.A.
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• Guardant Health
• Illumina, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

Countries Covered
• K.S.A.
• Israel
• U.A.E.
• Egypt
• Iran
• Qatar
• Rest-of-the-Middle East
Read the full report: https://www.reportlinker.com/p06282681/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting